Articles

Philadelphia International Airport (PHL)

Fitch Ratings Assigns Positive Outlook to Philadelphia International Airport Bonds, Affirms ‘A’ Rating

PHILADELPHIA, PA — In a recent development, Fitch Ratings, a globally recognized financial ratings agency, has assigned a positive outlook to the Revenue Bonds of Philadelphia International Airport (PHL) and …

Fitch Ratings Assigns Positive Outlook to Philadelphia International Airport Bonds, Affirms ‘A’ Rating Read More

aging

PA Department of Aging Underscores Importance of Preparedness for Older Pennsylvanians During National Preparedness Month

PENNSYLVANIA — September is National Preparedness Month (NPM), and the Pennsylvania Emergency Management Agency (PEMA) is partnering with the Pennsylvania Department of Aging (PDA) to encourage citizens to spend a …

PA Department of Aging Underscores Importance of Preparedness for Older Pennsylvanians During National Preparedness Month Read More
InterDigital

InterDigital’s Milind Kulkarni to Outline the 5G Journey to 6G Evolution at Mobile World Congress Las Vegas

WILMINGTON, DE — InterDigital, Inc. (Nasdaq: IDCC), has announced Milind Kulkarni, VP and Head of Wireless Labs, will headline a 6G conference session at Mobile World Congress Las Vegas, taking …

InterDigital’s Milind Kulkarni to Outline the 5G Journey to 6G Evolution at Mobile World Congress Las Vegas Read More

Consumer Financial Protection Bureau (CFPB)

CFPB Slams Leasing Company Tempoe with $36 Million Penalty for Deceptive Practices, Leaving Consumers in the Shadows

The Consumer Financial Protection Bureau (CFPB) recently took action against Tempoe, LLC for tricking consumers into expensive leasing agreements by concealing the contract terms and costs, and failing to provide …

CFPB Slams Leasing Company Tempoe with $36 Million Penalty for Deceptive Practices, Leaving Consumers in the Shadows Read More

Ocugen

Promising Update: Ocugen’s Gene Therapy for Retinitis Pigmentosa Shows Positive Results in Phase 1/2 Trial

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company, announced a clinical study update for Retinitis Pigmentosa (RP) participants treated in the Phase 1/2 trial to assess the safety …

Promising Update: Ocugen’s Gene Therapy for Retinitis Pigmentosa Shows Positive Results in Phase 1/2 Trial Read More